GLATIRAMER ACETATE INJECTION 20 MG
GLATIRAMER ACETATE : 20 MG · DIN 02541440 · MYLAN PHARMACEUTICALS ULC
Health Canada status: MARKETED
What is GLATIRAMER ACETATE INJECTION?
GLATIRAMER ACETATE INJECTION 20 MG contains GLATIRAMER ACETATE : 20 MG. It is listed in the Health Canada Drug Product Database under DIN 02541440, held by MYLAN PHARMACEUTICALS ULC, supplied as SOLUTION for SUBCUTANEOUS administration. Health Canada currently lists it as marketed, status dated 11-Apr-2024. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is GLATIRAMER ACETATE INJECTION used for?
Glatiramer Acetate Injection (glatiramer acetate) 20 mg/mL is indicated for: Treatment of ambulatory patients with Relapsing Remitting Multiple Sclerosis (RRMS), including patients who have experienced a single demyelinating event and have lesions typical of multiple sclerosis on brain MRI: To decrease the frequency of clinical exacerbations. To reduce the number and volume of active brain lesions identified on Magnetic Resonance Imaging (MRI) scans.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02541440 |
|---|---|
| Brand name | GLATIRAMER ACETATE INJECTION |
| Generic / active ingredient | GLATIRAMER ACETATE : 20 MG |
| Manufacturer | MYLAN PHARMACEUTICALS ULC |
| Strength | 20 MG |
| Dosage form | SOLUTION |
| Route of administration | SUBCUTANEOUS |
| Schedule | Prescription |
| ATC code | L03AX13 GLATIRAMER ACETATE |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 11-Apr-2024 |
How is it stored and handled?
null
How is it supplied?
Available in packs of 30 single-use 20 mg/mL pre-filled glass syringes.
Is GLATIRAMER ACETATE in shortage in Canada?
A Canadian shortage report is on file for a product containing this molecule: Resolved — reported by MYLAN PHARMACEUTICALS ULC, last seen 03 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code L03AX13 GLATIRAMER ACETATE. 4 of 8 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| COPAXONE | 20 MG | SOLUTION | TEVA CANADA LIMITED | MARKETED | DIN 02245619 |
| COPAXONE | 40 MG | SOLUTION | TEVA CANADA LIMITED | MARKETED | DIN 02456915 |
| GLATECT | 20 MG | SOLUTION | PHARMASCIENCE INC | MARKETED | DIN 02460661 |
| COPAXONE | 20 MG | POWDER FOR SOLUTION | TEVA PHARMACEUTICAL INDUSTRIES LTD | CANCELLED POST MARKET | DIN 02233014 |
| COPAXONE | 40 MG | SOLUTION | TEVA CANADA LIMITED | APPROVED | DIN 02512173 |
| TEVA-GLATIRAMER ACETATE | 20 MG | SOLUTION | TEVA CANADA LIMITED | APPROVED | DIN 02441446 |
| TEVA-GLATIRAMER ACETATE | 40 MG | SOLUTION | TEVA CANADA LIMITED | APPROVED | DIN 02481510 |
Who else supplies GLATIRAMER ACETATE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. GLATIRAMER ACETATE appears in 40 registered pack listings across 12 markets, published on 10 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.